FORSTEO

This brand name is authorized in Austria, Croatia, Cyprus, Estonia, Finland, France, Ireland, Italy, Lithuania, Netherlands, Poland, Romania, Spain, Turkey, UK.

Active ingredients

The drug FORSTEO contains one active pharmaceutical ingredient (API):

1	Teriparatide UNII 10T9CSU89I - TERIPARATIDE
	Teriparatide (rhPTH(1-34)) is the active fragment (1-34) of endogenous human parathyroid hormone. Teriparatide is a bone formation agent to treat osteoporosis. The skeletal effects of teriparatide depend upon the pattern of systemic exposure.
	Read more about Teriparatide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
FORSTEO Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
H05AA02	Teriparatide	H Systemic hormonal preparations, excl. Sex hormones and insulins → H05 Calcium homeostasis → H05A Parathyroid hormones and analogues → H05AA Parathyroid hormones and analogues
Discover more medicines within H05AA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1199910, 1199921, 1873773
ES	Centro de información online de medicamentos de la AEMPS	03247001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	014094
FR	Base de données publique des médicaments	61122200
GB	Medicines & Healthcare Products Regulatory Agency	196068
IE	Health Products Regulatory Authority	88384, 88494, 88718
IT	Agenzia del Farmaco	035926017, 035926029
LT	Valstybinė vaistų kontrolės tarnyba	1013131, 1013132
NL	Z-Index G-Standaard	15584844
NL	Z-Index G-Standaard, PRK	131601
PL	Rejestru Produktów Leczniczych	100125610
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W55488001, W55488002
TR	İlaç ve Tıbbi Cihaz Kurumu	8699673954295